Clinical StudiesResults Just In!

First Ever Human Clinical Study for

NOTE: This the study excluded patients with clear organic causes and risk factors of ED including vascular disease, diabetes mellitus, hypertension etc. Please see full report for complete exclusion criteria.

VigRX Plus Completed With
Outstanding Results, Including:
Here are VigRX Plus results:Vigrx-Plus-Order

  • 62.82% Increase inability to maintain erection
  • 58.97% Increase in ability to penetrate partner
  • 22.49% Increase in frequency and quality of orgasms
  • 71.43% Increase in sexual and intercourse satisfaction
  • 47.00% Increase in sex drive and desire
  • 61.00% Increase in overall sexual satisfaction

We knew VigRX Plus was extremely powerful but even we were shocked at the results of the first-ever human clinical study. But since we know everyone does not have time to read a 56-page clinical study that took us two years to complete, below we have included a “Study Summary” to highlight key points and findings of the test.

Summary of VigRX Plus Clinical Study Report

(Study Conducted By Research Organization: Vedic Lifesciences Pvt.)

The VigRX Plus clinical study was designed to evaluate the effectiveness and safety of VigRX Plus in erectile dysfunction and male sexual health.
The test parameters and methodology included:

Here are VigRX Plus Results:

75 males between the age of 25-50 years, selected based on specific criteria outlined in the study. The duration of the study was 84 days, with frequent visits, exams and questionnaires to track changes. Each subject was given the daily recommended dosage for the duration of the test.

The “International Index of Erectile Function”, initially created to measure the results of prescription medications were used to measure results of VigRX Plus. This was a randomized double-blind study, in which half the subjects were given VigRX Plus and the other half was given a placebo.

All increases and improvements were measured directly against results from the placebo group.

What is the “International Index of Erection Function” (IIEF)?

The IIEF is designed to be a reliable, self-administered questionnaire of erectile function in cross-cultural settings, detecting treatment-related changes in patients.

It was initially created by Raymond C. Rosen, Ph.D., Chief Scientist at the New England Research Institute, to measure the effectiveness of prescription medication used to treat erectile dysfunction.

By using this as the foundation of the VigRX Plus study, we were able to effectively measure the impact VigRX Plus had in numerous areas of the subject’s erection quality and sexual desire.

Further, this study also allowed us to gather feedback from the sexual partner of the subject in order to measure the satisfaction of both parties.

Efficacy Results Explained The following is a brief summary of key results. For more detail, please scroll to the bottom of this page to download the entire report. Result #1: 62.82% Increase inability in the ability to penetrate a partner. The inability to maintain an erection is a serious problem, affecting men of all ages. After taking VigRX Plus for 84 days, subjects saw a 62.82% improvement in their ability to maintain and control their erection when compared to the group taking placebo as demonstrated in the below chart.

Another important finding in this study was that the treatment satisfaction of the patients was also corroborated by their partners. In other words not only were the patients extremely satisfied with the results achieved when taking VigRX Plus, their partners also reported the same level of satisfaction. More specifically the female partners of the patients reported and 59.97% increase in penetration, dramatically increasing overall satisfaction. And while partner satisfaction of the VigRX Plus group actually increased during the study, the placebo group actually decreased over the same period! The chart below clearly demonstrates this substantial increase.

Leave a Reply

Your email address will not be published. Required fields are marked *